In AD, with cases having a range of CAA severity, changes to BBB proteins included decreased OCLN in several cortical regions as well as correlations to CAA severity particularly in the inferior temporal cortex as measured by ELISA in brain homogenate relative to CD31 levels [74]. This evidence concerns the gene PECAM1 and Alzheimer disease.